Blog / Archives
Volcano(VOLC) erupts 9% on Upgrade
Robert W. Baird and Co. analyst Lawrence Neibor upgraded four medtech stocks and helped get the "January effect" in full swing. Cyberonics (CYBX), Edwards Lifescience (EW), Thoratec (THOR) and...
Review of Biotech 2009 Fund and ETF Performance YTD
The Rayno LifeScience Biotech portfolio is up 11-15% YTD (15%+ with rebalancing as recommended). Among the big winners YTD are Regeneron (REGN) up 40%, Targacept (TRGT) up 880% and Inverness (IMA)...
CompuGen(CGEN) deal sparks small cap biodiscovery stocks
CompuGen, an early stage drug and diagnostic discovery Company announced today a "Discovery on Demand" therapeutic peptide collaboration with Pfizer that focuses on three peptide drugs based upon...
Year End Biotech Rally on Schedule
Seasonality, deals and "healthcare reform lite" spur rally On November 18 we suggested some rebalancing in the Rayno Life Science Portfolio anticipating some year-end optimism.Today we got some help...
Sequenom down 7.5% on Xenomics’ power play
Well known biotech executives "face-off" in Licensing Deal gone awry Xenomics'(XNOM.PK) announced today that an ongoing internal preliminary investigation concluded that Sequenom (SQNM) willfully...
H1N1 Boosts Development in Pharma Sector
Global market growth for vaccines forecasted at 12% ( Edited version published in Genetic Engineering News Dec. 1, 2009) The potential H1N1pandemic has drawn renewed interest in vaccines. Vaccines...
Positioning for a possible year-end Biotech Rally
After a nasty October correction of 10%, biotech stocks are in a recovery mode and poised for a Q4 rally extending to early January. This trend was intact in the past (check ’05,’06, and ’07 trends)...
Biotech stock rally continues: mid caps up 2.5%
Biotech stocks continue to rally off the early November bottom despite bad news from Poniard (PARD) because of the picoplatin study failure. PARD was down 76% at 12:09p. The recent news of...
Biotech sell-off abating
The technicals in the biotech market are looking a lot better but the damage from October was severe. The 10% correction from the Sep 21, 2009 peak is about over as long as the NASDAQ holds up. The...
Biotech sell-off continues
We commented on Tuesday about the broad selling of all biotech stocks large and small and this trend continues through today. AMGN shares are down this week despite earnings EPS of $1.49 beating...